Investigating how nickel can be used to create new pharmaceutical ingredients
Official title: Fundamental Studies of Ni-Catalyzed Organic Reactions
Funded at Yale University · NIH-10899407 · Data updated 2026-11-12
This study is exploring how nickel can be used instead of expensive metals to help create new medicines more efficiently, which could lead to better and more affordable treatments for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $418,750 |
| NIH project number | 5R35GM148260-02 |
| Project ID | NIH-10899407 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients who may benefit from this research are those requiring new or improved medications that are easier to produce and potentially more effective.
✕Less likely to help
Patients who are not seeking new medications or those with conditions not addressed by the types of drugs being developed may not receive any benefit.
What this research studies
This research focuses on using nickel as a more sustainable alternative to precious metals in the synthesis of active pharmaceutical ingredients (APIs). It aims to understand the mechanisms behind nickel-catalyzed reactions, particularly how they can form specific carbon-carbon bonds that are difficult to achieve with traditional methods. By synthesizing novel nickel complexes and studying their reactivity under various conditions, the research seeks to improve the efficiency and effectiveness of drug development. Patients may benefit indirectly through the potential for more accessible and effective medications resulting from these advancements.
Why it matters
Potential benefit: If successful, this research could lead to the development of more sustainable and effective pharmaceuticals.
How similar studies have gone: Other research has shown promise in using first-row transition metals like nickel for catalysis, indicating a potential for success in this novel approach.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Hazari, Nilay — Yale University
- Study coordinator: Hazari, Nilay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.